We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
Sterility and bioburden control are foundational to the safety of all parenteral pharmaceuticals, biologics, cell and gene therapies, and implantable medical devices. Sterility testing confirms the absence of viable microorganisms in the final product, while bioburden testing quantifies the total aerobic microbial count (TAMC) and total yeast and mold count (TYMC) in raw materials, in-process intermediates, and environmental samples. Under USP <71>, USP <61>, EP 2.6.1, and EP 2.6.12, these assays are mandatory for batch release, process validation, and regulatory filings. Profacgen’s Sterility and Bioburden Testing platform delivers comprehensive, compendial-compliant microbiological quality control—encompassing traditional culture-based methods, rapid microbiological methods (RMM), and environmental monitoring—to ensure your products are free from harmful microbial contamination and your manufacturing environment remains under control.
What Challenges Do We Solve?
Microbial contamination can arise from water systems, raw materials, personnel, equipment, and the manufacturing environment itself. Detecting and quantifying these contaminants—while avoiding false negatives from fastidious organisms or false positives from environmental background—presents significant analytical and operational challenges. Profacgen addresses the full spectrum of sterility and bioburden control:
Prolonged Culture Periods & Release Delays: Traditional compendial sterility testing requires 14 days of incubation, creating a major bottleneck for just-in-time manufacturing, short-shelf-life products, and autologous cell therapies with narrow administration windows
Fastidious & Viable-but-Non-Culturable (VBNC) Organisms: Standard growth media may fail to recover slow-growing, damaged, or stressed microorganisms—particularly in biologics subjected to low pH, freeze-thaw, or aseptic processing—risking false-negative sterility results
Bioburden Control & Trending: In-process intermediates, purified water, and raw materials require routine bioburden monitoring; without statistical process control and trending, gradual microbial ingress can escalate into batch-terminating contamination events
Complex Product Matrices: Cell and gene therapy products, lipid nanoparticles, viscous antibody formulations, and antibiotic-containing matrices can inhibit microbial growth or mask contamination, requiring validated neutralization and recovery strategies
Regulatory Scrutiny of Rapid Methods: While rapid microbiological methods (RMM) can deliver results in hours rather than days, FDA and EMA require rigorous validation demonstrating equivalence to compendial culture methods before RMM can substitute for release testing
Environmental & Personnel Monitoring: Cleanroom qualification, aseptic process simulation (media fill), and ongoing environmental monitoring are essential to demonstrate control; gaps in monitoring data can trigger regulatory observations and batch rejection
Our Core Platforms
Profacgen deploys a full suite of compendial and advanced microbiological platforms for sterility and bioburden determination. Each method is executed in ISO 5/7 cleanroom suites under strict aseptic technique, with validated media, calibrated instrumentation, and comprehensive documentation aligned to USP, EP, and ICH expectations.
Platform
Capabilities & Deliverables
Compendial Sterility Testing
Membrane filtration and direct inoculation methods per USP <71> and EP 2.6.1, using fluid thioglycollate medium (FTM) and soybean-casein digest medium (SCDM/TSA) with 14-day incubation at 30–35 °C and 20–25 °C
Validation of bacteriostasis and fungistasis neutralization for antibiotics, preservatives, and biologically active products
Aseptic processing simulation (media fill) support and sterility test method suitability for batch release and stability protocols
Bioburden / Microbial Limits Testing
Total aerobic microbial count (TAMC) and total yeast and mold count (TYMC) per USP <61> and EP 2.6.12 using membrane filtration, pour plate, or spread plate techniques
MALDI-TOF mass spectrometry and gene sequencing (16S rRNA for bacteria, ITS for fungi) for rapid, accurate identification of sterility test positives and environmental isolates
Root-cause analysis linking identified organisms to water systems, raw materials, personnel, or equipment via phenotypic and genotypic fingerprinting
Contamination recovery plans and corrective and preventive action (CAPA) documentation for regulatory response
Full Compendial Compliance: All sterility and bioburden assays are performed in strict accordance with USP <71>, USP <61>, EP 2.6.1, EP 2.6.12, and JP General Tests, with validated media, certified reference strains, and calibrated instrumentation.
Rapid Microbiological Method Expertise: Our validated RMM platforms—including ATP bioluminescence and flow cytometry—deliver results in 24–48 hours with demonstrated equivalence to compendial methods, supporting accelerated release for cell therapies and short-shelf-life products.
Complex Matrix Neutralization: We specialize in overcoming bacteriostatic and fungistatic interference from antibiotics, preservatives, high-protein formulations, and cytotoxic cell therapy products through validated membrane filtration, neutralizing diluents, and recovery optimization.
Integrated Environmental Monitoring: From cleanroom qualification and routine EM programs to isolate identification and root-cause analysis, we provide the complete environmental control data package required for regulatory inspection readiness.
Regulatory-Ready Documentation: Method suitability reports, validation protocols, bioburden trend analyses, CAPA narratives, and CTD-formatted control strategy documents are prepared for direct inclusion in IND, BLA, NDA, and MAA submissions.
Contamination Investigation & Recovery: When sterility positives or bioburden excursions occur, our microbial identification and forensic microbiology capabilities enable rapid root-cause determination and scientifically defensible remediation strategies.
A commercial-stage manufacturer required compendial sterility testing for every drug product lot of a high-concentration monoclonal antibody. The product contained a bacteriostatic preservative that inhibited microbial growth in preliminary method suitability testing, producing false-negative risks that would compromise patient safety and regulatory compliance.
Our Approach:
We performed USP <71> method suitability testing (bacteriostasis/fungistasis) using three compendial challenge organisms (Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans) at ≤ 100 CFU. The preservative suppressed recovery by 90% in undiluted product. We optimized a membrane filtration protocol with validated rinsing volumes (three × 100 mL) using neutralizing diluent containing Tween 80 and lecithin, achieving ≥ 70% recovery for all challenge strains. The validated method was transferred to routine QC.
Outcome:
All subsequent commercial lots passed sterility testing with documented neutralization efficacy. The method validation package was included in the post-approval CMC dossier and accepted by regulatory agency during routine inspection with no microbiological observations.
Scenario 2: Autologous Cell Therapy Rapid Release
Challenge:
An autologous CAR-T cell therapy developer faced a critical constraint: the final product had a 72-hour shelf life from harvest to infusion, making the 14-day compendial sterility test incompatible with patient administration timelines. The client needed a validated rapid microbiological method (RMM) approved by FDA CBER for lot-release decision-making.
Our Approach:
We implemented an ATP bioluminescence-based RMM platform and conducted a comprehensive method equivalence study per FDA guidance on alternative microbiological methods. Parallel testing of 50 spiked cell therapy samples compared the RMM to USP <71> membrane filtration. The RMM detected all positive samples within 24 hours with 100% sensitivity and 98% specificity relative to the compendial reference. A sterility test exemption petition was prepared with full validation and equivalence data.
Outcome:
FDA CBER granted approval for the RMM as a release test for the autologous product, contingent on concurrent 14-day compendial testing for retrospective confirmation. The client successfully released three clinical lots within the 72-hour window, enabling on-schedule patient dosing and avoiding treatment delays.
Q: What is the difference between sterility testing and bioburden testing?
A: Sterility testing (USP <71>, EP 2.6.1) is a qualitative assay that confirms the absence of viable microorganisms in the final product, requiring 14 days of incubation and demonstrating no microbial growth. Bioburden testing (USP <61>, EP 2.6.12) is a quantitative assay that measures the total aerobic microbial count (TAMC) and total yeast and mold count (TYMC) in raw materials, in-process samples, and environmental specimens, providing numerical data for process control and trending.
Q: Which regulatory guidelines govern sterility and bioburden testing?
A: USP <71> (Sterility Tests) and EP 2.6.1 govern final product sterility. USP <61> and EP 2.6.12 govern microbial limits and bioburden. ICH Q6B requires microbial purity specifications for biologics. FDA and EMA GMP guidances further specify expectations for aseptic processing, environmental monitoring, and rapid method validation.
Q: Can rapid microbiological methods (RMM) replace compendial sterility testing?
A: RMM can substitute for compendial release testing only after rigorous validation demonstrating equivalence to the reference method, per FDA and EMA guidance on alternative microbiological methods. Many sponsors employ RMM for accelerated release of short-shelf-life products (e.g., autologous cell therapies) while retaining concurrent 14-day compendial testing for retrospective confirmation and regulatory compliance.
Q: How does Profacgen handle products with antimicrobial properties that inhibit sterility test growth?
A: We perform method suitability testing (bacteriostasis/fungistasis) per USP <71> to identify inhibition. If the product suppresses microbial recovery, we apply validated neutralization strategies: membrane filtration with rinsing, dilution below the minimum inhibitory concentration, or neutralizing diluents containing Tween 80 and lecithin. All neutralization protocols are validated to ensure ≥ 70% recovery of compendial challenge organisms.
Q: What are alert and action limits for bioburden in pharmaceutical water systems?
A: For purified water (PW), typical alert limits are 10 CFU/mL and action limits are 100 CFU/mL for TAMC. For water for injection (WFI), limits are more stringent, typically 10 CFU/100 mL. These limits are established based on historical trending, risk assessment, and regulatory guidance; excursions require investigation, CAPA, and system requalification.
Q: How are environmental monitoring programs validated and maintained?
A: Environmental monitoring (EM) programs are established during cleanroom qualification and maintained through routine sampling of air (active and settle), surfaces, and personnel. Alert and action limits are set based on historical data and ISO 14644 cleanroom classifications. Profacgen identifies all environmental isolates to species level by MALDI-TOF MS or sequencing, enabling trend analysis, root-cause determination, and proactive contamination prevention.
Q: What is the typical timeline for sterility and bioburden testing?
A: Compendial sterility testing requires 14 days of incubation. Bioburden results are typically available in 3–5 days. Rapid microbiological methods can deliver sterility-equivalent results in 24–48 hours. Method suitability testing for a new product matrix requires 2–3 weeks, and full RMM equivalence validation requires 6–10 weeks. Expedited timelines are available for critical clinical batch release.
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
